1-2 of 2
Bruno Cazin, Dr.
Close
Sort by
Journal Articles

Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Updated Results From a Phase II Study of the Gcllsg and fcgcll/MW

Stephan Stilgenbauer, MD, Florence Cymbalista, MD, PhD, Veronique Leblond, Alain Delmer, MD, Silja Mack, MSc, Andreas Bühler, Dirk Winkler, Thorsten Zenz, MD, Raymonde Busch, Stefan Ibach, Sylvain Choquet, MD, Dartigeas Caroline, Bruno Cazin, Dr., Olivier Tournilhac, MD, PhD, Till M Seiler, MD, Katja Zirlik, Jürgen Alt, MD, Martin Sökler, MD, Johannes Schetelig, MD, Peter Dreger, MD, Michael Hallek, MD, Hartmut Döhner, MD
Journal: Blood
Blood (2012) 120 (21): 716.
https://doi.org/10.1182/blood.V120.21.716.716
Published: 2012
Journal Articles

Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Interim Analysis of a Phase II Study of the GCLLSG and fcgcll/MW

Stephan Stilgenbauer, Prof. Dr. med, Florence Cymbalista, Pr, Véronique Leblond, Pr, Alain Delmer, MD, Dirk Winkler, MD, Andreas Bühler, Dr. med., Thorsten Zenz, Prof. Dr. med., Silja Mack, Raymonde Busch, Dipl.-Math., Axel Hinke, Dr., Sylvain Choquet, MD, Caroline Dartigeas, Dr., Bruno Cazin, Dr., Olivier Tournilhac, MD, PhD, Michael Rieger, MD, Jürgen Alt, Dr. med, Martin Sökler, Dr. med, Johannes Schetelig, MD, Peter Dreger, Prof. Dr. med., Michael Hallek, MD, Hartmut Döhner, Prof. Dr. med.
Journal: Blood
Blood (2011) 118 (21): 2854.
https://doi.org/10.1182/blood.V118.21.2854.2854
Published: 2011